Sanofi

News and Events

Hand holding a liquid sample, preparing for mass spectrometry analysis

Second Quarter 2026 Results

Second quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation will be followed by a Q&A session.

Press Releases


July 1, 2026
Press Release: Availability of the aide-mémoire for Q2 2026 results

June 30, 2026
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

June 25, 2026
Press Release: Sanofi Foundation opens new chapter centered on future generations

Upcoming Events

30Jul

2026

Second quarter 2026 results

Second quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation will be followed by a Q&A session.

13:00 - 14:15 CET (7:00am - 8:15am EDT)

Quarterly results

Discover more

30Oct

2026

Third quarter 2026 results

Third quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on October 30, 2026. The presentation will be followed by a Q&A session.

13:00 - 14:00 CET (7:00am - 8:00am EDT)

Quarterly results


Past Events

23Apr

2026

First quarter 2026 results

Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.

Quarterly results

Discover more

29Jan

2026

Fourth quarter & full year 2025 results

Fourth quarter and full year 2025 results were reviewed by management during a live audio webcast with the financial community on January 29, 2026. The presentation was followed by a Q&A session.

Quarterly results

Discover more

24Oct

2025

Third quarter 2025 results

Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation was followed by a Q&A session.

Quarterly results

Discover more